BiotechTube

CNV1014802 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lumbosacral Radiculopathy

Conditions

Lumbosacral Radiculopathy

Trial Timeline

Apr 30, 2011 → Aug 31, 2012

NCT ID
NCT01561027

About CNV1014802 + Placebo

CNV1014802 + Placebo is a phase 2 stage product being developed by Biogen for Lumbosacral Radiculopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01561027. Target conditions include Lumbosacral Radiculopathy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT02359344Phase 1Completed
NCT01540630Phase 2Completed
NCT01561027Phase 2Completed

Competing Products

5 competing products in Lumbosacral Radiculopathy

See all competitors
ProductCompanyStageHype Score
VX-548 + PlaceboVertex PharmaceuticalsPhase 2
51
BIIB074 + PlaceboBiogenPhase 2
49
BIIB074BiogenPhase 2
49
SP-102 + PlaceboScilex HoldingPhase 3
69
SP-102Scilex HoldingPhase 2
44

Other Products from Biogen

Interferon-beta-1a + methylprednisoloneApproved
82
Dimethyl fumarateApproved
82
[18F]Florbetapir PET imagingApproved
82
dimethyl fumarateApproved
82
ibritumomab tiuxetan (Zevalin®)Approved
82